Impact of complications in adult anterior uveitis in a Finnish single-centre registry study Authors: Aada Leino, Mira Siiskonen, Pasi Ohtonen, Nina Maria Hautala Published: 2025 ABSTRACT AbstractObjectiveTo analyse ocular complications, their surgical treatments and risk factors in anterior uveitis (AU).Methods and analysisFrom a single-centre registry of all adult patients with AU in 2009 (n=413), ocular complications of 641 uveitic eyes, their operative treatments and risk factors were studied comparing patients with or without complications.ResultsA total of 269 (42%) uveitic eyes and 189 (46%) patients had ocular complications. The most common complication was cataract in 217 (34%) eyes. Glaucoma was noted in 69 (11%) eyes, cystoid macular oedema in 39 (6%), posterior synechiae in 30 (5%), band keratopathy and optic disc oedema in 11 (2%), and iris atrophy and cystic corneal oedema in one eye (0.2%). Complications were typically observed in the chronic course of AU, without notable sex difference and with non-infectious aetiology. A steroid response, the course of uveitis, eye involvement, oral, subconjunctival and prophylactic dosage of steroids, methotrexate and immunosuppressants management formed significant risk factors for complication development in AU. Respectively, significant risk was also observed with the steroid response in the development of complications other than glaucoma.ConclusionsA remarkable portion of eyes affected by AU—two out of five—develop ocular complications during long follow-up. Our results highlight the significance of uveitic inflammation and its corticosteroid treatment leading to earlier onset of cataract, glaucoma and their surgical treatments. For the first time, a significant risk was observed between the number of corticosteroid responders and the development of complications, extending beyond glaucoma. The retrospective design of the study can be considered as the main limitation of the study. WHAT IS ALREADY KNOWN ON THIS TOPIC Anterior uveitis (AU) has been considered to be less vision threatening compared with other anatomical sites of uveitis. However, there is a limited amount of studies from adult chronic and recurrent AU, its prognosis and complications. Anterior uveitis (AU) has been considered to be less vision threatening compared with other anatomical sites of uveitis. However, there is a limited amount of studies from adult chronic and recurrent AU, its prognosis and complications. WHAT THIS STUDY ADDS Comprehensive understanding of frequencies, clinical features and operative management of ocular complications in adult AU patients. Impact of uveitic inflammation and corticosteroid treatment on earlier onset of cataract, glaucoma and their surgeries. Increased risk of complications by corticosteroid response, course of uveitis, corticosteroid management, methotrexate and immunosuppressant treatments. Especially, the significant risk of corticosteroid response to the development of other complications than glaucoma. Comprehensive understanding of frequencies, clinical features and operative management of ocular complications in adult AU patients. Impact of uveitic inflammation and corticosteroid treatment on earlier onset of cataract, glaucoma and their surgeries. Increased risk of complications by corticosteroid response, course of uveitis, corticosteroid management, methotrexate and immunosuppressant treatments. Especially, the significant risk of corticosteroid response to the development of other complications than glaucoma. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY: These results highlight the importance of regular follow-ups of recurrent and chronic courses of AU in order to detect and manage possible ocular complications. The result also implies that other treatments than steroids should be taken into consideration with corticosteroid responder patients at an earlier stage to reduce the risk of complication development. However, further research is needed to address this connection. These results highlight the importance of regular follow-ups of recurrent and chronic courses of AU in order to detect and manage possible ocular complications. The result also implies that other treatments than steroids should be taken into consideration with corticosteroid responder patients at an earlier stage to reduce the risk of complication development. However, further research is needed to address this connection. Introduction Uveitis is an inflammation of the uveal tract, that is, iris, ciliary body and choroid. In addition, adjacent structures can be affected, such as anterior chamber, vitreous, sclera and optic nerve head.1 Anterior uveitis (AU) is the most common anatomical site of inflammation with 90% of patients in community-based studies and around 50% in tertiary care centres.2 Uveitis typically affects patients of working age, with the onset between 20 and 50 years.3 Despite its rarity, uveitis and its ocular complications create a potential threat for vision, accounting for 10%–15% blindness.4 Accordingly, the economic impacts of the disease are substantial for both society and for the individuals affected.5 Several ocular complications may develop due to uveitic inflammation and its treatments.4 Respectively, untreated and prolonged inflammation in an eye can result in additional pathologies.6 Most frequent complications of AU are cataract, secondary glaucoma, posterior synechiae (PS), cystoid macular oedema (CME), band keratopathy and epiretinal membrane.7 The complexity of uveitis is broadly studied worldwide.5 However, the amount of research conducted concerning AU’ complications, management and outcomes remains limited. This study, based on a Finnish single-centre registry of adult patients with AU, focuses on describing uveitic complications and analysing the differences between patients who develop complications and those who do not. The study examines the demographic characteristics, clinical features, clinical outcomes and visual prognosis of patients with complications, their surgical treatments and the time from the diagnosis of uveitis to the onset of complications. Additionally, by comparing the patients according to the existence of complications, we aim to recognise potential risk factors for complications’ development. Materials and methods The study population consisted of adult AU patients treated and followed up at the Ophthalmology Department of Oulu University Hospital in 2009 (n=591). Patients’ diagnoses were by ICD-10 codes H20.0 (acute and subacute iridocyclitis) or H20.1 (chronic iridocyclitis). Only the anterior anatomical site of inflammation was concerned. Adult patients were included, defined as age at onset ≥17 years. Furthermore, patients were required to have at least one follow-up visit in addition to the initial one and each control visit had to be conducted at Oulu University Hospital ensuring access to the full ophthalmologic records for each patient. Based on these criteria, the final data included 413 patients. Clinical parameters were gathered from both the initial and the final visits of the follow-up. The earliest available data was from the year 1998, and data collection was completed at the records of the end of 2018. Classification of the anatomical location, chronicity of uveitis and clinical findings was based on the Standardisation of Uveitis Nomenclature classification.8 The term ‘corticosteroid responder’ was defined as a patient with a rise of intraocular pressure (IOP) by ≥10 mm Hg or above 21 mm Hg due to any administration of steroids. The treatments used by the study participants have been documented in our recent study.9 The term ‘steroid prophylaxis’ refers to the long-term administration of low-dose topical corticosteroids aimed at preventing disease recurrences. The data were analysed using SPSS (IBM, Released 2021., IBM SPSS Statistics for Windows, V.28.0) and SAS (V.9.4, SAS Institute). The statistical significance was assessed between patients of complicated and uncomplicated uveitis. In patient-level analysis, complicated uveitis was defined as the presence of at least one complication in either one or both eyes affected by uveitis, while uncomplicated uveitis was characterised by the absence of additional pathologies. However, in eye-level analysis, the eyes with and without complications were compared. The statistical tests used were the χ2 test, Fisher’s exact test and the Mann-Whitney U test. When the analyses of clinical outcomes were performed at the eye level, a generalised linear mixed model was used using patient as a random effect, and parameters initial value and the follow-up time as fixed effects. Two-tailed p values <0.05 are reported. Additionally, the parameters for each separate complication are presented; however, statistical comparison was not conducted, as analysing the compartment of complications was not the focus of this study. Patient and public involvement Patients and the public were not involved in this study. Results A total of 269 (42%) uveitic eyes and 189 (46%) patients had at least one ocular complication during the long active follow-up. Most complicated eyes (68%) had a single complication, and the third was affected by two to four complications (table 1). The most common complication was cataract in 217 (34%) eyes. Glaucoma was noted in 69 (11%) eyes, CME in 39 (6%), PS in 30 (5%), band keratopathy and optic disc oedema (ODE) in 11 (2%), and iris atrophy and cystic corneal oedema in one eye (0.2%). Table 1Demographics and clinical features in complicated versus uncomplicated uveitisComplicationsNo complicationsP valuePatientsn189224EyesN269372Age at the onset of uveitisMean, SD42±1541±170.28*Age groups of uveitis initiation (%)17–3989 (47)121 (54)0.048†40–5977 (41)66 (29)60–23 (12)37 (17)Sex (%)Female91 (48)113 (50)0.69†Course of uveitis (%)Acute8 (4)64 (29)<0.001†Recurrent32 (17)66 (29)Chronic149 (79)94 (42)Eye involvement in uveitis (%)Unilateral68 (36)117 (52)<0.001†Bilateral121 (64)107 (48)Aetiology (%)Idiopathic83 (44)112 (50)0.64†Systemic disease73 (39)77 (34)Infectious14 (7)11 (5)Post-operative11 (6)15 (7)Traumatic8 (4)9 (4)Active follow-up period, yearsMean, SD11.7±5.85.8±5.8<0.001*Number of ocular complications in an eye (%)1183 (68)0264 (24)0319 (7)043 (1)0*Mann-Whitney U test.†χ2 test. Demographics and clinical features in complicated versus uncomplicated uveitis Mann-Whitney U test. χ2 test. The average age of AU initiation was almost equal in complicated uveitis patients with 42±15 years (95% CI 39.2 to 43.6) and uncomplicated uveitis patients with 41±17 years (95% CI 40.0 to 44.3). However, the significance (p=0.048) in age distribution was noted when comparing patients in age groups of 17–39, 40–59 and 60 years, as complications were more common with patients of 40–59 years old. Gender distribution was even in both groups, with the complicated group representing 91 females and 98 males and the uncomplicated group 113 females and 111 males, respectively. The course of uveitis (p<0.001) and eye involvement (p<0.001) were recognised risk factors for complication development. A major part of patients (79%) with complications had a chronic course of AU, as recurrent (17%) and acute (4%) courses were more infrequent. In contrast, patients with uncomplicated uveitis presented a more equal division of courses with 42% chronic, 29% recurrent and 29% acute AU. Therefore, the active follow-up period of patients with complications was longer with 11.7±5.8 years vs 5.8±5.8 years in patients without complications, p<0.001. Involvement of both eyes in uveitis was more common in patients with complications (64%) compared with (48%) patients without any. In both groups, the majority of patients had non-infectious aetiology of idiopathic and systemic disease-associated AU. The average ages at the diagnosis of separate complications were in the working age, with band keratopathy occurring at the oldest age of 59±17 years (95% CI 47.0 to 71.3) and ODE in notably younger age of 31±7 years (95% CI 20.5 to 31.8). Most complication’s diagnosis ages were normally distributed as the median was almost equal to the mean. As an exception, the median age of glaucoma was lower at 48 years (mean 52 years) and the median age of CME was higher at 55 years (mean 51 years). The shortest duration from uveitis’ diagnosis to the onset of complication was observed in ODE with the mean of 4.3±7.1 years (95% CI −1.1 to 9.8, median 1.0 year) and the longest duration in band keratopathy with the mean of 16.4±13.2 (95% CI 7.0 to 25.9, median 13.4 years) in figure 1. The age and duration from uveitis to PS were not available, as we only recorded PS as a complication if it was evident at the final follow-up visit. In contrast, other complications were recorded if observed at any time during the follow-up period. The patients’ sex, course and aetiology of uveitis in separate complications are presented in table 2. Kaplan-Meier survival function of complications from the initiation of anterior uveitis. Table 2Demographics, clinical features and time period of complication development in different complicationsCataractGlaucomaCMEPSBand keratopathyODEPatientsn149523424109Diagnostic age of complicationMean, SD53±1452±1651±17NA59±1731±7Age groups of uveitis initiation17–3967 (45)27 (52)18 (53)12 (50)4 (40)9 (100)40–5965 (44)17 (33)13 (38)10 (42)5 (50)0 (0)60-17 (11)8 (15)3 (9)2 (8)1 (10)0 (0)Initial age of uveitisMean, SD42±1542±1641±1541±1243±1726±7Duration from uveitis to complication, yearsMean, SD11.2±10.79.7±9.29.3±9.6NA16.4±13.24.3±7.1Sex (%)Female76 (51)27 (52)16 (47)12 (50)7 (70)6 (67)Course (%)Acute5 (3)3 (6)0 (0)2 (8)0 (0)0 (0)Recurrent23 (15)3 (6)6 (18)4 (17)0 (0)0 (0)Chronic121 (81)46 (88)28 (82)18 (75)10 (100)9 (100)Aetiology (%)Idiopathic68 (46)21 (40)13 (38)12 (50)6 (60)2 (22)Systemic disease62 (42)18 (35)16 (47)9 (38)2 (20)7 (78)Infectious9 (6)4 (8)1 (3)3 (13)0 (0)0 (0)Postoperative4 (3)4 (8)1 (3)0 (0)0 (0)0 (0)Traumatic6 (4)5 (10)3 (9)0 (0)2 (20)0 (0)CME, cystoid macular oedema; NA, not available; ODE, optic disc oedema; PS, posterior synechiae. Demographics, clinical features and time period of complication development in different complications CME, cystoid macular oedema; NA, not available; ODE, optic disc oedema; PS, posterior synechiae. The clinical outcomes were favourable regardless of the existence of complications when comparing IOP and amount of inflammation in the last visit to the initial one (table 3). The mean visual acuity had slightly decreased in both groups. Complicated eyes had a significantly greater decrease in visual acuity with the mean of −4±22 (95% CI −7.1 to −1.8) compared with eyes without complications with the mean of −1±13 (95% CI −2.3 to 0.3). Patients with cataract had a decrease in visual acuity by the average of −6 ETDRS letters, respectively, in glaucoma −11 letters, in CME −9 letters and −14 letters in band keratopathy were noted. ODE was associated with an improvement of visual acuity by 7 ETDRS letters. During the long-term follow-up, IOP decreased by 1–5 mm Hg with complicated uveitis patients, whereas a 1 mm Hg increase in IOP was noted with uncomplicated uveitis patients. The reduction in inflammation was defined as a decrease in cell count at the final visit compared with the initial visit, or a cell count of zero at both visits. Conversely, an increase in inflammation was defined as either an increase or no change in cell count. In both groups, a reduction in cell count was most frequently observed; however, 17% of eyes in the complicated group and 13% of eyes in the uncomplicated group exhibited either an increase or stability in active disease. Visual impairment (best-corrected visual acuity (BCVA)<0.30) and blindness (BCVA<0.05) was rare in all patients. There were nine (5%) patients with complications and four (2%) patients without complications at the end of follow-up with visual impairment. Two patients with uncomplicated and three patients with complicated uveitis met the criterion for legal blindness. These visually impaired and blind patients had complications of cataract, glaucoma, CME and band keratopathy (table 4). Table 3Clinical outcomes, visual prognosis and treatments in complicated versus uncomplicated uveitisComplicationsNo complicationsP valuePatientsn189224EyesN269372Eye-level Clinical outcomes (end-initiation) Change of visual acuity, ETDRSMean, SD−4±22−1±130.029* Change of IOPMean, SD−1±81±60.46* Inflammation (anterior chamber cells) (%)Reduced222 (83)324 (87)0.19*Increased47 (17)48 (13)Patient-level Visual impairment (BCVA<0.30) (%)Initiation4 (2)2 (1)0.42†At the end of follow-up9 (5)4 (2)0.083‡ Blindness (BCVA<0.05) (%)Initiation2 (1)0 (0)0.21†At the end of follow-up3 (2)2 (1)0.66†Uveitis management (%) Topical steroids189 (100)224 (100)1.00‡ Oral steroids75 (40)24 (11)<0.001‡ Ozurdex3 (2)0 (0)0.095† Subconjunctival steroids39 (21)23 (10)0.003‡ Methotrexate25 (13)12 (5)0.005‡ Immunosuppressants11 (6)3 (1)0.012‡ Biologics10 (5)8 (4)0.39‡ Steroid prophylaxis110 (58)50 (22)<0.001‡ Steroid responders (%)92 (49)51 (23)<0.001‡*Generalised linear mixed model.†Fisher’s exact test.‡χ2 test.BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure. Clinical outcomes, visual prognosis and treatments in complicated versus uncomplicated uveitis Generalised linear mixed model. Fisher’s exact test. χ2 test. BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure. Table 4Clinical outcomes, visual prognosis and treatments in different complicationsCataractGlaucomaCMEPSBand keratopathyODEPatientsn149523424109EyesN2176939301111Eye-level Clinical outcomes Visual acuity, ETDRSMean, SD−6±22−11±30−9±28−1±20−14±207±22 IOPMean, SD−1±8−5±13−1±9−2±8−2±9−1±4 Inflammation (anterior chamber cells) (%)Reduced180 (83)56 (81)34 (87)25 (83)9 (82)9 (82)Increased37 (17)13 (19)5 (13)5 (17)2 (18)2 (18)Patient-level Visual impairment (BCVA<0.30) (%)At the end of follow-up8 (5)4 (8)2 (6)0 (0)1 (10)0 (0) Blindness (BCVA<0.05) (%)3 (2)1 (2)1 (3)0 (0)1 (10)0 (0)Uveitis management (%) Topical steroids149 (100)52 (100)34 (100)24 (100)10 (100)9 (100) Oral steroids60 (40)21 (40)21 (62)12 (50)3 (30)6 (67) Ozurdex1 (1)0 (0)3 (9)0 (0)1 (10)1 (11) Subconjunctival steroids32 (21)12 (23)11 (32)7 (29)3 (30)5 (56) Methotrexate21 (14)7 (13)9 (26)3 (13)1 (10)1 (11) Immunosuppressants10 (7)4 (8)2 (6)1 (4)1 (10)1 (11) Biologics9 (6)3 (6)2 (6)1 (4)0 (0)0 (0) Steroid prophylaxis87 (58)43 (83)20 (59)10 (42)9 (90)6 (67) Steroid responders (%)72 (48)40 (77)14 (41)8 (33)7 (70)3 (33)BCVA, best-corrected visual acuity; CME, cystoid macular oedema; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; ODE, optic disc oedema; PS, posterior synechiae. Clinical outcomes, visual prognosis and treatments in different complications BCVA, best-corrected visual acuity; CME, cystoid macular oedema; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; ODE, optic disc oedema; PS, posterior synechiae. Surprisingly, other complications than glaucoma also showed a larger proportion of steroid responders than 23% of the patients with no complications. We defined a steroid responder as an individual with a rise of IOP by ≥10 mm Hg or above 21 mm Hg due to steroid management. The highest steroid responders’ frequencies were noted with 48% patients in cataract, 70% in band keratopathy and 77% in glaucoma. Steroid response was associated with increased risk for complications with significance (p<0.001) between complicated and uncomplicated uveitis. Respectively, significant risk was also observed with the steroid response in the development of complications other than glaucoma, p=0.002. Management of AU included more frequently oral (p<0.001) and subconjunctival (p=0.003) administrations of steroids, methotrexate (MTX) (p=0.005) and immunosuppressant (p=0.012) in complicated patients compared with uncomplicated ones. Respectively, all patients received topical corticosteroids as a treatment of AU. Additionally, steroid prophylaxis was needed in 58% of patients with complications compared with 22% of uncomplicated ones (p<0.001). Uveitis management with intravitreal dexamethasone and biologics was rare in all patients (table 3). The most common operation performed was uveitic cataract surgery in 124 eyes, at the average age of 58±15 years (95% CI 55.3 to 61.5). Notably, the youngest patient that underwent cataract surgery was 21 years old. Uveitic cataract surgery was performed by an average of 12±12 years (95% CI 10.0 to 14.8) after uveitis diagnosis. Glaucoma surgery was performed in 47 uveitic eyes at the average age of 53±16 years (95% Cl 46.5 to 58.6). The most common technique was Baerveldt implant surgery performed in 17 patients at the age of 56±13 years (95% CI 48.8 to 63.3). Other techniques used were 12 Molteno implant surgeries at the age of 50±20 years (95% CI 35.6 to 64.0), 10 deep sclerotomies at the age of 56±15 years (95% CI 44.1 to 68.4), and one trabeculectomy at the age of 65 years. 45 (65%) uveitic glaucoma eyes underwent at least one surgical or laser treatment during the follow-up. 28 (41%) uveitic glaucoma patients received laser treatment, some of them multiple different ones. These included 20 cyclophotocoagulations, 12 iridotomies, seven goniopunctures, four laser trabeculoplasties and iridoplasties, three cryocoagulations and single iridectomy, sclerectomy and sphincterotomy. Discussion Untreated and prolonged uveitic inflammation can result in additional ocular pathologies.6 AU has been considered to be less vision-threatening compared with other anatomical sites of inflammation; however, there is a limited amount of studies from adult chronic and recurrent AU, its prognosis and complications.7 In the present single-centre registry study, ocular complications occurred in 42% of eyes with AU during the long-term follow-up period. Most complications were associated with idiopathic or systemic disease-associated aetiologies and chronic course of AU. For the first time, corticosteroid responders were shown to have significantly elevated risk for the development of other ocular complications than glaucoma. Our study population contained all courses of AU. However, the proportion of chronic cases (42%–79%) was deviant from previous knowledge as 11%–31% of AU has been considered to be chronic or recurrent.7 Recurrent cases alone accounted for 17%–29% of cases depending on the existence of complications. One possible factor explaining the larger proportions of chronic and recurrent patients is the long follow-up period and the method we collected the data. Since uveitis is a reasonably uncommon disease, only a limited number of acute courses come up in a year, but the chronic course requires long-term controls, so the number of patients accumulates. Therefore, our data best presents the occurrence of complications in chronic and recurrent courses. By previous knowledge, the most common complications of AU are cataract, glaucoma, PS, CME and epiretinal membrane.7 Other uveitic complications include band keratopathy, ODE, ocular hypotony and iris atrophy.6 10 11 There is no previous research on the overall proportion of adult AU patients who develop complications, as earlier studies have focused on the frequencies of specific complications. In paediatric AU, the rates of at least one complication have varied between 20% nd 40%.1214 Our result in adults was aligned with previous knowledge from paediatric patients as 42% eyes had some complication during the average active follow-up of 8.5 years. Development of uveitic cataract is a combination of the inflammation of uveitis, frequent corticosteroid treatment and age-related changes in lens.15 16 Uveitic cataract is typically associated with chronic and recurrent courses.17 Our result was parallel as most cataract patients (81%) had chronic or (15%) recurrent course of AU. Two previous studies have reported the prevalence of cataract as AU complication to be around 18%–40%.18 19 Respectively, in our study, the proportion was at the higher end of previous knowledge with 36%. In a large study from the USA, the mean age at age-related cataract enrolment was 62 years.20 Our uveitic patients’ cataract was detected nearly a decade earlier at the average age of 53 years. In previous studies, 26%–30% of uveitis patients undergo cataract surgery, whereas our result represented a smaller proportion of 19%.15 One possible reason explaining the smaller proportion of surgeries was that we only documented cataract and its surgery if the diagnosis was made after uveitis’, and solely age-related cataracts were excluded. In the Finnish general population, the median age of cataract surgery has been 74 years, whereas in the USA the corresponding age was 68 years.20 21 In our data, the mean age for uveitic cataract surgery was younger, 58 years, which implicates the significance of uveitis’ inflammation and corticosteroid treatments in the development of cataract. The indications for the surgery are the same for age-related and uveitic cataract in Finland. Around 6%–20% of patients with uveitis develop glaucoma.2224 In our study, the proportion was in the middle, with 12% having diagnosed glaucoma. The development of glaucoma has been typically associated with the chronic course of uveitis.25 In agreement with this, 88% of uveitic glaucoma in our data was observed with chronic courses and only a minority was associated with acute and recurrent courses. In a previous Finnish study, the mean age of the most common type of glaucoma, primary open-angle glaucoma, was 68 years and female sex was predominant with 66%.26 In our study, uveitic glaucoma was diagnosed at a significantly younger age of 52 years and female (52%) predominance was not deviant. Also, a small Dutch study had revealed a younger mean age of uveitic glaucoma of 44 years old and a New Zealand study median of 48 years old.23 24 Uveitic glaucoma management is complex because of the simultaneous need to address inflammation and elevated IOP.23 There are several different surgical options to manage uveitic glaucoma. Trabeculectomy is less frequently used because of the young age of patients with AU, among other factors making it a non-optimal choice. Glaucoma drainage devices are usually favoured. Around 30% of uveitic glaucoma patients require surgical treatment due to insufficient IOP control.27 In our study, 65% of patients received some surgical or laser treatment for uveitic glaucoma, and the rate of surgical treatment was higher in 49% compared with previous study. CME has been shown to occur in 5%–11% of AU patients in previous studies.11 24 28 Our result was parallel with 8% of patients. In a previous New Zealand study, the median age of uveitic CME was 53, which was nearly equal to the mean of 52 years in our study.24 CME has been the most common cause of vision loss in uveitis by previous knowledge.29 This was not noted in our data. ODE is a relatively uncommon complication of AU, with previous studies reporting a prevalence of papillitis between 8% and 14%.3032 In our study, the prevalence was even lower, with 2% of patients. In a large US cohort study, the prevalence of band keratopathy in AU was 3%, which was parallel with 2% in our study population.28 Prevalence of PS in uveitis has varied between 19% and 21%.28 33 34 In our study, PS was observed in only 6% of patients. However, the result of our study is not comparable as we only noted those patients who had chronic PS, that is, synechiae were observed at the final visit of follow-up. Hence, we did not collect the information whether a patient had PS in any stage of AU. The decision to include PS only if present at final follow-up visit underestimates occurrence of the complication and may be considered as a limitation of this study. The visual prognosis in AU has been considered to be fairly good, comparing other sites of uveitis.7 In previous studies, AU has been characterised with stable visual acuity in long follow-up periods and with low rates of visual impairment.7 24 29 Our results were parallel, as most patients had only a slight decrease of −1 to −6 ETDRS letters during the long-term follow-up. However, patients with complications of glaucoma, CME and/or band keratopathy were associated with more significant decreases in vision. Visual impairment and blindness were uncommon in our data regardless of ocular complications. To our knowledge, our results demonstrate for the first time that the response to corticosteroids is indicative of an increased risk of complication development in AU. Significance (p=0.002) was also observed comparing proportion of corticosteroid responders in uncomplicated uveitis vs complications other than glaucoma (38%). We did not find any previous studies addressing this connection of corticosteroid response as a sign of increased risk of complication development. All administrations of corticosteroids have been shown to be associated with elevated risk of cataract and secondary glaucoma.11 In our study, significantly increased risk of complication development was noted in oral, subconjunctival and prophylactic administration of steroids. In addition, the use of MTX and immunosuppressants, that is, leflunomide and azathioprine, increased the risk of complications; these risks were possibly due to prolonged and/or severe inflammation requiring management beyond steroids. Our results indicate that a significant proportion of eyes with AU—two out of five—develops at least one complication. However, the large proportion of chronic courses may have an influence. Results highlight the significance of uveitic inflammation and its corticosteroid treatment leading to earlier onset of cataract, glaucoma and their surgical treatments. However, MTX has recently replaced corticosteroids in certain cases of chronic, frequently recurrent or complicated AU, which might have reduced the rate for ocular complications. Despite the high number of complications in the present study cohort, visual stability and low rate of blindness showed favourable prognosis for AU, suggesting that current management strategies are effective to save vision. Interestingly, complicated uveitis patients showed a higher proportion of steroid responders, also beyond glaucoma. The frequent follow-ups and several treatments required for both uveitis and ocular complications point to a substantial economic and quality-of-life burden associated with AU.